{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:36:12Z","timestamp":1793284572185,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015631","name":"Organon Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023517","name":"Sandoz Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023517","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018592","name":"Celltrion Pharm Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ard.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:22:48Z","timestamp":1787948568000},"page":"2129-2135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7837","authenticated-orcid":false,"given":"Andreu","family":"Fern\u00e1ndez-Codina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-2490","authenticated-orcid":false,"given":"Susan J.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-190X","authenticated-orcid":false,"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-3741","authenticated-orcid":false,"given":"Glen","family":"Hazlewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5818-4880","authenticated-orcid":false,"given":"Marie-France","family":"Valois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-2658","authenticated-orcid":false,"given":"Hughes","family":"Allard-Chamard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-2731","authenticated-orcid":false,"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-3268","authenticated-orcid":false,"given":"Carol A.","family":"Hitchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3370-0006","authenticated-orcid":false,"given":"Bindee","family":"Kuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1219-3845","authenticated-orcid":false,"given":"Vivian P.","family":"Bykerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.08.001_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.001_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2017-000536","article-title":"Glucocorticoids in rheumatoid arthritis: current status and future studies","volume":"6","author":"Hua","year":"2020","journal-title":"RMD open."},{"key":"10.1016\/j.ard.2026.08.001_bib0003","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/rheumatology\/kex271","article-title":"The use of glucocorticoids in early rheumatoid arthritis","volume":"57","author":"Verschueren","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.08.001_bib0004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.001_bib0005","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3899\/jrheum.2024-0540","article-title":"Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2","volume":"51","author":"Nikolic","year":"2024","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.08.001_bib0006","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00296-015-3229-x","article-title":"High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort","volume":"35","author":"Albrecht","year":"2015","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.ard.2026.08.001_bib0007","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/annrheumdis-2016-210135","article-title":"Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort","volume":"76","author":"Roubille","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.001_bib0008","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/acr2.11334","article-title":"A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian early arthritis cohort","volume":"4","author":"Andersen","year":"2022","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.ard.2026.08.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152219","article-title":"Time trends in glucocorticoid use in rheumatoid arthritis during the biologics era: 1999-2018","volume":"61","author":"Crowson","year":"2023","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.08.001_bib0010","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3899\/jrheum.120029","article-title":"The Canadian Early Arthritis Cohort (CATCH): Patients with new-onset synovitis meeting the 2010 ACR\/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity","volume":"39","author":"Bykerk","year":"2012","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.08.001_bib0011","first-page":"373","article-title":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects","volume":"79","year":"2001","journal-title":"Bull World Health Organ."},{"key":"10.1016\/j.ard.2026.08.001_bib0012","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.22456","article-title":"Validation of the rheumatic disease comorbidity index","volume":"67","author":"England","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2026.08.001_bib0013","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00124743-199908000-00004","article-title":"The effectiveness of the clinical self-assessment (MHAQ) compared with other clinical and laboratory tests used to monitor the activity of rheumatoid arthritis by consensus analysis","volume":"5","author":"Finley","year":"1999","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.ard.2026.08.001_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.08.001_bib0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/TP.0b013e3182845f23","article-title":"Outcomes in systemic sclerosis-related lung disease after lung transplantation","volume":"95","author":"Sottile","year":"2013","journal-title":"Transplantation."},{"key":"10.1016\/j.ard.2026.08.001_bib0016","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/ard-2022-223443","article-title":"Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis","volume":"82","author":"van Ouwerkerk","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.001_bib0017","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ard.2025.03.002","volume":"84","author":"Hetland","year":"2025","journal-title":"Ann Rheum Dis."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:07:11Z","timestamp":1793282831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726004863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0003496726004863"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.001","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}